Vanguard Group Inc. Buys 1,407,651 Shares of Hims & Hers Health, Inc. $HIMS

Key Points

• Vanguard increased its stake in Hims & Hers by 7.2% in Q4, buying 1,407,651 shares to hold 20,925,666 shares (about 9.19%), valued at $679.46 million.
• Analysts are mixed: the consensus rating is Hold with a $32.53 price target, though JPMorgan initiated coverage at "Overweight" with a $35 target and several firms have lowered or revised ratings.
• Insiders have been net sellers recently—204,857 shares worth $5.29 million sold in the last 90 days—while institutional investors collectively own 63.52% of the company.

Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 7.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,925,666 shares of the company's stock after purchasing an additional 1,407,651 shares during the quarter. Vanguard Group Inc. owned 9.19% of Hims & Hers Health worth $679,456,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HIMS. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. Invesco Ltd. lifted its position in Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company's stock valued at $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Clear Street Group Inc. bought a new position in Hims & Hers Health during the third quarter valued at $87,372,000. BIT Capital GmbH lifted its position in Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock valued at $125,373,000 after purchasing an additional 938,728 shares during the last quarter. Finally, State of Michigan Retirement System lifted its position in Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock valued at $116,713,000 after purchasing an additional 678,600 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Hims & Hers Health in a research report on Friday, April 24th. They set an "overweight" rating and a $35.00 price objective for the company. Truist Financial reiterated a "hold" rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. BTIG Research lowered shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a research report on Tuesday, February 24th. Needham & Company LLC upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research report on Monday, March 9th. Finally, Bank of America increased their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a "neutral" rating in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $32.53.

Insider Activity

In other news, insider Irene Becklund sold 5,529 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the sale, the insider owned 8,752 shares of the company's stock, valued at approximately $216,086.88. This represents a 38.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 19,645 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $29.96, for a total transaction of $588,564.20. Following the completion of the sale, the chief financial officer directly owned 262,954 shares in the company, valued at approximately $7,878,101.84. This represents a 6.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 204,857 shares of company stock worth $5,285,706. Insiders own 17.71% of the company's stock.

Hims & Hers Health Trading Down 0.2%

Shares of HIMS opened at $27.36 on Monday. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a market cap of $6.24 billion, a P/E ratio of 53.65, a P/E/G ratio of 2.84 and a beta of 2.43. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The company's fifty day simple moving average is $21.91 and its 200-day simple moving average is $30.40.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the firm posted $0.11 earnings per share. The business's revenue for the quarter was up 28.4% on a year-over-year basis. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.56 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.